Translational Pharmaceutics® Case Studies: Proven across 500+ programs

Quotient Sciences applied the Translational Pharmaceutics® platform to help a clinical‑stage biotech company overcome modified release formulation challenges and achieve its first‑in‑human trial milestone.

Ensysce Biosciences, a San Diego–based biotechnology company focused on improving the safety and oral delivery of pain management therapies, required a development approach that could support accelerated timelines without compromising formulation performance. 

After consultations with other CDMO providers suggested extended development timelines, Ensysce Biosciences partnered with Quotient Sciences to address CMC and formulation development hurdles by applying the Translational Pharmaceutics® integrated drug development platform.

Choosing Quotient Sciences as an integrated CRDMO enabled earlier clinical evaluation of a modified release small‑molecule formulation for Ensysce Biosciences' PF614‑MPAR. The program supported faster decision‑making and reduced development risk for first‑in‑human studies.

Drawing on experience from more than 300 programs where we've optimized drug products, this webinar explores practical approaches to solubility enhancement and modified release development, including spray dried dispersions, lipid formulations, and small‑molecule products. 

Watch our featured webinar for expert perspectives and more case studies on using clinical data to reduce uncertainty and support phase‑appropriate formulation strategies.